There are no data on the quality, effectiveness and safety of the Russian vaccine against coronavirus. This was announced on August 11 by a representative of the German Ministry of Health.
“The approval of a vaccine in Europe provides, along with confirmation of pharmaceutical quality, the provision of sufficient information gleaned from clinical trials to prove its effectiveness and harmlessness,” the editorial association Redaktionsnetzwerk Deutschland quoted him as saying.
The Ministry of Health stressed that before using the vaccine, it is necessary to prove “a positive balance of benefits and risks.” It is noted that the drug has not yet passed the third phase of the study. In this regard, Germany is not negotiating “vaccine development” with Moscow.
On August 11, Russian President Vladimir Putin announced the registration of the first coronavirus vaccine in Russia. The drug was developed by the Center. N. Gamalei, it was named “Sputnik V” by analogy with the launch of the first artificial Earth satellite in 1957.
The first recipients of the vaccine from the Gamaleya Center will be health workers and the elderly. The effectiveness of the drug will be assessed based on the results of the formation of population immunity.